[
  {
    "ts": "2025-12-11T08:12:15+00:00",
    "headline": "Why Analysts See Biogen’s Story Shifting Toward Undervalued Growth Potential",
    "summary": "Biogen's fair value estimate has nudged higher to about $178.76 per share, even as its discount rate ticks up slightly to roughly 7.49 %, signaling a modestly higher perceived risk backdrop. The shift reflects a cautiously constructive Street narrative that balances near term execution risks with growing confidence in longer term drivers such as Leqembi, the core neurology franchise, and late stage pipeline assets. Stay tuned to learn how you can track these evolving assumptions and the...",
    "url": "https://finance.yahoo.com/news/why-analysts-see-biogen-story-081215764.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "b33fcaa8-75aa-3635-937a-a2ef1945b3f8",
      "content": {
        "id": "b33fcaa8-75aa-3635-937a-a2ef1945b3f8",
        "contentType": "STORY",
        "title": "Why Analysts See Biogen’s Story Shifting Toward Undervalued Growth Potential",
        "description": "",
        "summary": "Biogen's fair value estimate has nudged higher to about $178.76 per share, even as its discount rate ticks up slightly to roughly 7.49 %, signaling a modestly higher perceived risk backdrop. The shift reflects a cautiously constructive Street narrative that balances near term execution risks with growing confidence in longer term drivers such as Leqembi, the core neurology franchise, and late stage pipeline assets. Stay tuned to learn how you can track these evolving assumptions and the...",
        "pubDate": "2025-12-11T08:12:15Z",
        "displayTime": "2025-12-11T08:12:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I2k3PKJsWIEX9xgEQz8JwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tmSjpFKmBAT61w1lG5.BLQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-analysts-see-biogen-story-081215764.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-analysts-see-biogen-story-081215764.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "JEF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T07:10:02+00:00",
    "headline": "Does Biogen’s Recent Share Price Rebound Reflect Its True Value in 2025?",
    "summary": "If you have been wondering whether Biogen's recent share price makes it a bargain or a value trap, you are not alone. This article is designed to help you cut through the noise and focus on what the numbers are really saying. The stock has climbed 13.6% over the last month and is up 18.4% year to date, even though it is still down sharply over 3 and 5 years. That hints at a possible shift in how the market is reassessing its long term prospects and risk profile. Recent headlines have...",
    "url": "https://finance.yahoo.com/news/does-biogen-recent-share-price-071002863.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "7f617bc7-c278-345e-ba4f-4bc9d0d0bd92",
      "content": {
        "id": "7f617bc7-c278-345e-ba4f-4bc9d0d0bd92",
        "contentType": "STORY",
        "title": "Does Biogen’s Recent Share Price Rebound Reflect Its True Value in 2025?",
        "description": "",
        "summary": "If you have been wondering whether Biogen's recent share price makes it a bargain or a value trap, you are not alone. This article is designed to help you cut through the noise and focus on what the numbers are really saying. The stock has climbed 13.6% over the last month and is up 18.4% year to date, even though it is still down sharply over 3 and 5 years. That hints at a possible shift in how the market is reassessing its long term prospects and risk profile. Recent headlines have...",
        "pubDate": "2025-12-11T07:10:02Z",
        "displayTime": "2025-12-11T07:10:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I2k3PKJsWIEX9xgEQz8JwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tmSjpFKmBAT61w1lG5.BLQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/does-biogen-recent-share-price-071002863.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/does-biogen-recent-share-price-071002863.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]